Early Detection Research Network
Team Project

Standard Specimen Reference Set: Colon

COLON CANCER REF
251
Brenner, DeanUniversity of Michigan
Feng, ZidingFred Hutchinson Cancer Research Center
N/A
No design specified.
Other, Specify
[u'G.I. and Other Associated Cancers Research Group']

The Early Detection Research Network, Great Lakes-New England Clinical, Epidemiological and Validation Center (GLNE CVC) announces the availability of serum, plasma and urine samples for the early detection for colon cancer and validation studies.

Two prospective studies were used to collect samples to make this reference set. GLNE 001, (Preliminary Clinical Characterization of Serum, Plasma, and Urine Biomarkers for Colorectal Neoplasms) was a prospective, cross-sectional clinical trial to collect serum, plasma, urine, and common data elements on subjects undergoing routine screening colonoscopy or subjects undergoing surgery or endoscopy for colon cancer. GLNE 007 (Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas) is an on-going prospective, cross-sectional clinical to collect serum, plasma, urine, stool, and common data elements. In both protocols, subjects were undergoing routine colonoscopy (or being seen in surgery clinic for colorectal cancer) when the samples were collected. Samples were collected while the target lesions were still in place in the colon. Subjects were either normal (without adenomas or cancer), with pathologically confirmed adenomas or pathologically confirmed colorectal adenocarcinoma. Exclusion criteria for both protocols included known hepatitis C or HIV, ulcerative colitis, Crohns’s Disease or IBD, history of cancer within 3 years, or genetic colon diseases including FAP or HNPCC. Samples were collected from 4 sites around North America.
N/A

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.